

Type-IV, and antibody titers.

RESULTS

Epidemiological outcomes. The cohort of 139 subjects ranged in age from 9 to 69 years old, and the male/female sex ratio was 92/47. Table 1 shows the relationships between aging and markers of fibrosis in our patient population. We adopted four indicators to estimate the degree of liver fibrosis: ultrasonographic (US) score, and serum levels of procollagen-III-peptide (P-III-P), type-IV collagen (Type-IV), and total bile acids (TBA).

Age showed a strong correlation with US score ($R = 0.488$, $p < 0.001$), but was not correlated with P-III-P or Type-IV level. In addition, US score was correlated with P-III-P and Type-IV levels ($R = 0.306$, $p = 0.003$; $R = 0.278$, $p = 0.011$, respectively). On the other hand, TBA level was not correlated with aging, US score, or other serological markers (data not shown).

Relationships between aging and antibody isotype responses against PM. To determine whether isotype responses against PM are associated with age-dependent resistance in Filipino patients, we measured the serum levels of IgA, IgE, IgG1, IgG2, IgG3, and IgG4 against PM and AWA (Fig. 1). As the reactivity of secondary antibodies used for ELISA varied, it was difficult to determine the amounts of antibody among the isotypes. With the exception of IgG2, the levels of all of the antibody isotype against PM and AWA increased significantly in patients infected with *S. japonicum*. The unresponsiveness of IgG2 production against AWA in Filipino patients was consistent with previous findings in Chinese patients with schistosomiasis japonica.¹⁸

We selected IgA, IgE, IgG1, IgG3, and IgG4 isotypes to examine the relationships

between aging and their responses against AWA and PM (Table 2). Aging was correlated positively with serum levels of IgG3 against both AWA ($R = 0.313, p = 0.0003$) and PM ($R = 0.241, p = 0.0057$) and with the level of IgA against PM ($R = 0.180, p = 0.034$). This was, in part, consistent with the findings of a previous report, in which anti-AWA IgA level was correlated with aging and PM was a major target of the IgA response in the Philippines.⁹ IgE, IgG1, and IgG4 responses did not show such correlations with aging.

Relationships between fibrosis and antibody isotype responses against PM. To determine whether isotype response levels against PM are associated with fibrosis, we examined the relationships between fibrosis and levels of IgA, IgE, IgG1, IgG3, and IgG4 against PM in patients with schistosomiasis japonica. We observed that correlations of isotype responses with fibrosis were different among the indicators of fibrosis, US score and serum levels of P-III-P and Type-IV (Table 3). With US score, positive correlations were observed for IgA, IgG3, and IgG4 levels against PM. In contrast, P-III-P level was correlated positively only with IgG3 to PM and Type-IV level was associated with no isotype responses to PM.

Unexpectedly, IgE levels against PM correlated negatively with serum P-III-P level ($R = -0.260, p = 0.0028$, Table 3), in which individuals showing high IgE titers developed lower levels of serum P-III-P. Such trends were also observed between the US score and level of IgE to PM, ($R = -0.069, p = 0.44$) and between type-IV collagen and IgE level ($R = -0.107, p = 0.23$).

IgG1 responses to AWA were correlated positively with US score ($R = 0.320, p = 0.0002$), while no such correlations were observed against PM. These results suggest that fibrosis associated with IgG1 responses may be attributable to other parasite antigens.

Epitope analyses of PM recognized by isotypes. In light of these findings, we attempted to identify the epitopes recognized by IgA, IgE, IgG3, and IgG4 isotypes that are associated with age-dependent resistance or fibrosis in *S. japonicum* infection. We constructed a series

of deletion mutants, PM1 (1--164 amino acids), PM2 (157--302 amino acids), PM3 (297--451 amino acids), PM4 (447--602 amino acids), PM5 (597--742 amino acids), and PM6 (734--866 amino acids). These truncated mutants had an average length of 150 amino acid residues and provided a sequential overlap of at least five residues (Fig. 2). The minor bands of PM2 and PM5 were probably degraded proteins, as the mouse antisera raised against *S. japonicum* PM reacted with these bands (data not shown).

Box-and-whisker plots of isotype responses demonstrated the presence of low responders and high responders for antibody production against the full-length PM and its deletion mutants (Fig. 3). Among the deletion mutants, PM6 hardly evoked antibody production for any antibody isotype. IgA and IgG3 isotypes reacted predominantly with the first three PM mutants, PM1, PM2, and PM3. In contrast, IgG4 appeared to react predominantly with PM2, PM3, PM4, and PM5, while IgE did not show such specificity.

IgA and IgG3 response levels against PM1, PM2, and PM3, and IgG3 levels against PM5 were correlated positively with aging (Table 3). These results suggest that the PM epitopes recognized by IgA and IgG3 in association with age-dependent resistance are likely to be distributed within the N-terminal half of PM.

With regard to fibrosis, IgG3 levels against any of the deletion mutants showed no significant correlations with US score, despite the positive correlation between US score and IgG3 level against full-length PM. The PM epitopes associated with fibrosis were recognized differently by IgA and IgG4. That is, IgA levels to PM2 and PM3 and IgG4 levels to PM1, PM4, and PM5 showed positive correlations with US score.

Negative correlations between IgE titers and P-III-P levels were observed for PM3, PM4, PM5, and PM6, while IgE responses against these deletion mutants were very weak. These results were consistent with the relationship between IgE levels and full-length PM, and suggest that the C-terminal part of PM recognized by IgE play a role in suppression of

the progression of fibrosis.

DISCUSSION

Relationships between aging and fibrosis in patients with schistosomiasis japonica in the Philippines. Schistosome vaccines are expected to show both anti-infection and anti-disease effects. In the present study, we addressed the relationships of antibody isotype responses to paramyosin not only with age-dependent resistance but also with fibrosis, as liver fibrosis is the most important lesion in schistosomiasis japonica.

To determine the epidemiological states of schistosomiasis japonica patients in the Philippines, we first examined the relationships between aging and fibrosis (Table 1). We observed a positive correlation between aging and US score but not between aging and any serological markers of fibrosis. Correlations between aging and US score appear to reflect accumulation of fibrosis along with aging rather than the current progression of fibrosis. For example, old cases of schistosomiasis japonica in Japan, showing advanced liver fibrosis by US scoring, excrete no eggs.²⁶

Positive correlations of US score with P-III-P and Type-IV levels are consistent with the previous findings in case of schistosomiasis japonica.^{24,27} It is noteworthy that P-III-P level reflects mainly the progress of collagen synthesis, while the Type IV level reflects collagen degradation.²⁸ Thus, correlations between US score and these serological markers may reflect the current pathological progress.

TBA level has been suggested to be an good indicator of hepatic fibrosis.²⁵ In the present study, however, TBA level did not show any correlations with other indicators of fibrosis. This discrepancy may have been due to the difference in duration between the

previous²⁵ and the present study design, in that the subjects in the present study had received mass treatment with praziquantel in the previous 10 years, which may have influenced the serum level of TBA .

Involvement of PM-specific IgG3 and IgA in age-dependent resistance to *S. japonicum* infection. We showed that levels of IgG3 to both AWA and PM were correlated positively with aging (Table 2). A similar age-related trend with these IgG3 responses was reported previously in the human population in the Philippines.^{7,29} These findings suggest that IgG3 responses to PM may be involved in protective immunity to *S. japonicum* infection.

Likewise, IgA responses to PM were correlated positively with aging (Table 2). This was consistent with the previous report of a positive correlation between IgA levels against PM and aging in Filipino patients.⁹ In contrast, there was no correlation between any antibody responses to PM and aging in China.¹⁸ Thus, the correlation between levels of IgA to PM and aging is likely to be distinctive in the Philippines, possibly due to differences in epidemiological and immunological features between China and the Philippines.

We did not find any correlations between IgE levels and aging, whereas AWA- and PM-specific IgE were present in the sera of Filipino patients. Similarly, we found no significant correlations between IgE levels and frequency of treatment, a representative of intensity of reinfection (data not shown). These observations were consistent with the report that levels of IgE against AWA did not show correlations with aging.^{18,29} In contrast, levels of IgE to AWA were higher in subjects who were unsusceptible to reinfection 2 years post-treatment in China.⁸ Another group has also reported an association between IgE response to AWA and aging in the Philippines.⁷ Since there is no direct evidence that human IgE in combination with effector cells mediates killing of the parasites, further analyses are necessary to explain this discrepancy by verifying the precise role of IgE in age-dependent resistance.

Different modes of PM-specific IgG3 and IgE responses in progression of fibrosis. In the present study, the relationships between antibody response levels to PM and the degree of liver fibrosis were investigated. We observed positive correlations of the antibody isotypic responses to PM with the degree of liver fibrosis as follows: the IgA, IgG3, and IgG4 levels with US score and IgG3 level with P-III-P (Table 3). These results suggest that PM-specific IgA, IgG3, and IgG4 are likely to be associated with granuloma formation. It is important to note that US score is likely to represent accumulation of fibrous tissues in the liver, while serum P-III-P level indicates the currently active state of fibrosis.²⁸ Therefore, IgG3 response to PM may predominantly enhance antibody-dependent granuloma formation.

Surprisingly, a negative correlation between IgE response and serum P-III-P level was found in the Filipino patients in the present study (Table 3), while animal experiments using a rodent model indicated a contribution of IgE in granulomatous development.^{19,20} The discrepancy in the mode of IgE in granulomatous development may suggest that the roles of IgE in fibrosis are dependent on parasite antigens; IgE to PM may interfere with the progression of fibrosis, while other combinations may enhance fibrosis.

Recent studies have demonstrated the roles of surface PM as immunomodulators. PM is capable of binding *in vitro* to collagen and the complement components, C1, C8, and C9, resulting in inhibition of complement activation and of membrane attack complex (MAC) formation.³⁰⁻³² Likewise, PM can bind to the Fc domain of immunoglobulin *in vitro*.³³ The modes of isotype responses to PM in granuloma formation are unclear. However, it is possible that the immune complex of immunoglobulins and PM released from the parasite surface binds to the endothelial or fibroblastic matrix surrounding the embolized eggs through interaction of PM with collagen, leading to enhanced inflammation and granuloma formation.

Importance of recombinant vaccine design. In the present study, it was difficult to identify

the epitope(s) responsible for age-dependent resistance or granuloma formation. Epitope mapping of PM recognized by the isotypes and their correlation analyses indicated some trends, in that aging tended to be associated with the responses to the N-terminal half of PM (Table 2). In contrast, no such tendency was observed in relationships between liver fibrosis and the epitopes. These results suggest that multiple epitopes are involved in both age-dependent resistance and liver fibrosis.

A positive correlation between IgG3 responses to PM and P-III-P levels was an undesirable finding in the context of schistosome vaccine development. In contrast, IgE response to PM is likely to play a suppressive role in the development of fibrosis, a desired feature for a schistosome vaccine. These contrasting results clearly indicate that PM has complex roles in modulating human immune responses.

Although PM can induce protective immunity against challenge parasite infection in experimental animal models, there are marked immunological and etiological differences between humans and animals. Our findings provide insights into the importance of combinations between PM and isotype responses for schistosome vaccine development, in which the desired immune responses should be provoked to avoid exacerbating the pathology. Further studies to characterize the precise mode of PM in antibody-dependent killing of the parasite and in granuloma formation in humans are required prior to clinical trials.

Acknowledgments: We sincerely thank all patients for their willingness to participate in this study and Schistosomiasis Research Hospital staffs at Palo, Leyte, the Philippines, for their technical assistance.

Financial support: This work was supported in part by grants-in-aid for scientific research (Nos. 15390138, 15659102, 17590377, and 17390123) from the Ministry of Education,

Science, Sports, Culture, and Technology of Japan, from Ohyama Health Foundation (to TN), and from Kampou Science Foundation (to TN). T.A was supported by a Grant-in-Aid for the 21st Century COE Research from the Ministry of Education, Science, Sports, Culture, and Technology of Japan.

Authors' address: Takeshi Nara, Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan, Telephone: +81-3-5802-1043, Fax: +81-3-5800-0476, E-mail: tnara@med.juntendo.ac.jp. Kyoichi Iizumi, Soichi Tsubota, and Takashi Aoki, Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. Hiroshi Ohmae, Laboratory of Imported Parasitic Diseases, Department of Parasitology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan. Orlando S. Sy, Schistosomiasis Research Hospital, Palo, Leyte, the Philippines. Masanobu Tanabe, Department of Tropical Medicine and Parasitology, School of Medicine, Keio University, Tokyo 160-8582, Japan. Somei Kojima, Center for Medical Sciences, International University of Health and Welfare, Kitakanamaru 2600-1, Otawara, Tochigi 324-8501, Japan.

Reprint requests: Takeshi Nara, Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.

REFERENCES

1. Kabatereine NB, Vennervald BJ, Ouma JH, Kemijumbi J, Butterworth AE, Dunne

- DW, Fulford AJ, 1999. Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. *Parasitology 118 (Pt 1)*: 101--105.
2. Woolhouse ME, Taylor P, Matanhire D, Chandiwana SK, 1991. Acquired immunity and epidemiology of *Schistosoma haematobium*. *Nature 351*: 757--759.
 3. Li YS, Sleigh AC, Ross AG, Li Y, Williams GM, Forsyth SJ, Tanner M, McManus DP, 1999. A 2-year prospective study in China provides epidemiological evidence for resistance in humans to re-infection with *Schistosoma japonicum*. *Ann Trop Med Parasitol 93*: 629--642.
 4. Acosta LP, Aligui GD, Tiu WU, McManus DP, Olveda RM, 2002. Immune correlate study on human *Schistosoma japonicum* in a well-defined population in Leyte, Philippines: I. Assessment of 'resistance' versus 'susceptibility' to *S. japonicum* infection. *Acta Trop 84*: 127--136.
 5. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA, 1991. Human IgE, IgG4 and resistance to reinfection with *Schistosoma haematobium*. *Nature 349*: 243--245.
 6. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, Capron A, Pierce RJ, Sturrock RF, 1992. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. *Eur J Immunol 22*: 1483--1494.
 7. Webster M, Libranda-Ramirez BD, Aligui GD, Olveda RM, Ouma JH, Kariuki HC, Kimani G, Olds GR, Fulford AJ, Butterworth AE, Dunne DW, 1997. The influence of sex and age on antibody isotype responses to *Schistosoma mansoni* and *Schistosoma japonicum* in human populations in Kenya and the Philippines. *Parasitology 114 (Pt 4)*: 383--393.
 8. Li Y, Sleigh AC, Ross AG, Zhang X, Williams GM, Yu X, Tanner M, McManus DP,

2001. Human susceptibility to *Schistosoma japonicum* in China correlates with antibody isotypes to native antigens. *Trans R Soc Trop Med Hyg* 95: 441--448.
9. Hernandez MG, Hafalla JC, Acosta LP, Aligui FF, Aligui GD, Ramirez BL, Dunne DW, Santiago ML, 1999. Paramyosin is a major target of the human IgA response against *Schistosoma japonicum*. *Parasite Immunol* 21: 641--647.
 10. Ndhlovu P, Cadman H, Vennervald BJ, Christensen NO, Chidimu M, Chandiwana SK, 1996. Age-related antibody profiles in *Schistosoma haematobium* infections in a rural community in Zimbabwe. *Parasite Immunol* 18: 181--191.
 11. Butterworth AE, Bensted-Smith R, Capron A, Capron M, Dalton PR, Dunne DW, Grzych JM, Kariuki HC, Khalife J, Koech D, et al., 1987. Immunity in human schistosomiasis mansoni: prevention by blocking antibodies of the expression of immunity in young children. *Parasitology* 94 (Pt 2): 281--300.
 12. Bergquist R, Colley D, 1999. Schistosome vaccines: Research to development. *Parasitol Today* 14: 99--104.
 13. Chen H, Nara T, Zeng X, Satoh M, Wu G, Jiang W, Yi F, Kojima S, Zhang S, Hirayama K, 2000. Vaccination of domestic pig with recombinant paramyosin against *Schistosoma japonicum* in China. *Vaccine* 18: 2142--2146.
 14. McManus DP, Wong JY, Zhou J, Cai C, Zeng Q, Smyth D, Li Y, Kalinna BH, Duke MJ, Yi X, 2001. Recombinant paramyosin (rec-Sj-97) tested for immunogenicity and vaccine efficacy against *Schistosoma japonicum* in mice and water buffaloes. *Vaccine* 20: 870--878.
 15. Janecharut T, Hata H, Takahashi H, Yoshida S, Saito H, Kojima S, 1992. Effects of recombinant tumour necrosis factor on antibody-dependent eosinophil-mediated damage to *Schistosoma japonicum* larvae. *Parasite Immunol* 14: 605--616.
 16. Nara T, Matsumoto N, Janecharut T, Matsuda H, Yamamoto K, Irimura T, Nakamura

- K, Aikawa M, Oswald I, Sher A, et al., 1994. Demonstration of the target molecule of a protective IgE antibody in secretory glands of *Schistosoma japonicum* larvae. *Int Immunol* 6: 963--971.
17. Kojima S, Niimura M, Kanazawa T, 1987. Production and properties of a mouse monoclonal IgE antibody to *Schistosoma japonicum*. *J Immunol* 139: 2044--2049.
18. Li YS, Ross AG, Sleigh AC, Li Y, Waine GJ, Williams GJ, Tanner M, McManus DP, 1999. Antibody isotype responses, infection and re-infection for *Schistosoma japonicum* in a marshland area of China. *Acta Trop* 73: 79--92.
19. King CL, Xianli J, Malhotra I, Liu S, Mahmoud AA, Oettgen HC, 1997. Mice with a targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with *Schistosoma mansoni*. *J Immunol* 158: 294--300.
20. Owhashi M, Nawa Y, Watanabe N, 1989. Granulomatous response in selective IgE-deficient SJA/9 mice infected with *Schistosoma japonicum*. *Int Arch Allergy Appl Immunol* 90: 310--312.
21. Silveira AM, Bethony J, Gazzinelli A, Kloos H, Fraga LA, Alvares MC, Prata A, Guerra HL, Loverde PT, Correa-Oliveira R, Gazzinelli G, 2002. High levels of IgG4 to *Schistosoma mansoni* egg antigens in individuals with periportal fibrosis. *Am J Trop Med Hyg* 66: 542--549.
22. Hirsch C, Zouain CS, Alves JB, Goes AM, 1997. Induction of protective immunity and modulation of granulomatous hypersensitivity in mice using PIII, an anionic fraction of *Schistosoma mansoni* adult worm. *Parasitology* 115 (Pt 1): 21--28.
23. Hirsch C, Carvalho-Queiroz C, Franco GR, Pena SD, Simpson AJ, Goes AM, 1997. Evidentiatioin of paramyosin (Sm-97) as a modulating antigen on granulomatous hypersensitivity to *Schistosoma mansoni* eggs. *Mem Inst Oswaldo Cruz* 92: 663--667.

24. Ohmae H, Tanaka M, Hayashi M, Matsuzaki Y, Kurosaki Y, Blas BL, Portillo GG, Sy OS, Irie Y, Yasuraoka K, 1992. Improvement of ultrasonographic and serologic changes in *Schistosoma japonicum*-infected patients after treatment with praziquantel. *Am J Trop Med Hyg* 46: 99--104.
25. Ohmae H, Tanaka M, Hayashi M, Matsuzaki Y, Kurosaki Y, Blas BL, Portillo GG, Sy OS, Irie Y, Yasuraoka K, 1992. Ultrasonographic and serologic abnormalities in *Schistosoma japonicum* infection in Leyte, the Philippines. *Am J Trop Med Hyg* 46: 89--98.
26. Ohmae H, Sy OS, Chigusa Y, Portillo GP, 2003. Imaging diagnosis of schistosomiasis japonica--the use in Japan and application for field study in the present endemic area. *Parasitol Int* 52: 385--393.
27. Li YS, Sleigh AC, Ross AG, Li Y, Williams GM, Tanner M, McManus DP, 2000. Two-year impact of praziquantel treatment for *Schistosoma japonicum* infection in China: re-infection, subclinical disease and fibrosis marker measurements. *Trans R Soc Trop Med Hyg* 94: 191--197.
28. Tsukamoto T, Yamamoto T, Ikebe T, Takemura S, Shuto T, Kubo S, Hirohashi K, Kinoshita H, 2004. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver. *Hepatogastroenterology* 51: 777--780.
29. Acosta LP, McManus DP, Aligui GD, Olveda RM, Tiu WU, 2004. Antigen-specific antibody isotype patterns to *Schistosoma japonicum* recombinant and native antigens in a defined population in Leyte, the Philippines. *Am J Trop Med Hyg* 70: 549-555.
30. Deng J, Gold D, LoVerde PT, Fishelson Z, 2003. Inhibition of the complement membrane attack complex by *Schistosoma mansoni* paramyosin. *Infect Immun* 71: 6402--6410.
31. Laclette JP, Shoemaker CB, Richter D, Arcos L, Pante N, Cohen C, Bing D,

- Nicholson-Weller A, 1992. Paramyosin inhibits complement C1. *J Immunol* 148: 124--128.
32. Parizade M, Arnon R, Lachmann PJ, Fishelson Z, 1994. Functional and antigenic similarities between a 94-kD protein of *Schistosoma mansoni* (SCIP-1) and human CD59. *J Exp Med* 179: 1625--1636.
33. Loukas A, Jones MK, King LT, Brindley PJ, McManus DP, 2001. Receptor for Fc on the surfaces of schistosomes. *Infect Immun* 69: 3646--3651.

LEGENDS TO FIGURES

FIGURE 1. Antibody isotype levels (geometric mean \pm SE) against *S. japonicum* adult worm antigens (AWA) and PM (PM) in healthy (open bar) and infected (gray bar) individuals (uninfected, $n = 8$; infected, $n = 139$). * $p < 0.01$.

FIGURE 2. Schematic representation of recombinant *S. japonicum* paramyosin (PM) and its deletion derivatives used in this study. The scale and numbers indicate the amino acid positions. The full-length PM consists of 866 amino acids. The deletion mutants and their amino acid positions were as follows; PM1 (1--164 amino acids), PM2 (157--302 amino acids), PM3 (297--451 amino acids), PM4 (447--602 amino acids), PM5 (597--742 amino acids), and PM6 (734--866 amino acids).

FIGURE 3. Box-and-whisker plots of IgA, IgE, IgG3, and IgG4 isotype responses to *S. japonicum* paramyosin and its deletion mutants. The full-length paramyosin (PM) and a series of deletion mutants (PM1, PM2, PM3, PM4, PM5, and PM6) were used for ELISA.

The box indicates the area ranging from the first to the third quartiles of each dataset and the median is indicated by the black centerline. The vertical bar represents 1.5 times the inter-quartile range (IQR) from the upper or lower quartile. Points at a greater distance from the IQR are plotted individually as circles.

TABLE 1

Correlations between aging and markers of fibrosis in schistosomiasis japonica patients in Leyte, the Philippines.

Markers	Correlation coefficient (<i>R</i>) (<i>p</i> value)			
	US score	P-III-P*	Type-IV*	TBA*
Aging	0.488 (< 0.001)	0.039 (0.65)	0.126 (0.14)	0.044 (0.61)
US score	-	0.306 (0.003)	0.278 (0.001)	0.023 (0.79)
P-III-P	-	-	0.670 (< 0.001)	-0.147 (0.09)
Type-IV	-	-	-	0.056 (0.52)

*Transformed into \log_{10}

TABLE 2

Correlations between antibody isotype levels (\log_{10}) to *Schistosoma japonicum* antigens and aging.

Antibody	Correlation coefficient (R) by antigen							
	AWA	PM	PM1	PM2	PM3	PM4	PM5	PM6
IgA	0.138	0.226¹	0.150	0.234¹	0.335¹	0.117	0.113	0.004
IgE	-0.064	0.031	0.113	0.041	-0.004	-0.060	-0.027	0.016
IgG1	0.093	0.113	(-)	(-)	(-)	(-)	(-)	(-)
IgG3	0.216²	0.325¹	0.268¹	0.254¹	0.183²	0.030	0.223²	0.090
IgG4	0.111	0.152	0.126	0.108	0.231¹	0.114	0.239¹	0.084

¹ $p < 0.01$, ² $p < 0.05$.

R values for IgG1 responses to the truncated PMs are not shown.

TABLE 3

Correlations between antibody isotype levels (\log_{10}) to antigens of *Schistosoma japonicum* and various markers of fibrosis.

Antibody	Correlation coefficient (<i>R</i>) by antigen							
	AWA	PM	PM1	PM2	PM3	PM4	PM5	PM6
US score								
IgA	0.143	0.180²	0.109	0.280	0.180²	0.128	0.124	0.111
IgE	0.035	-0.069	0.031	-0.020	-0.111	-0.124	-0.130	-0.204²
IgG1	0.320¹	0.081	(-)	(-)	(-)	(-)	(-)	(-)
IgG3	0.313¹	0.241¹	0.017	0.151	0.156	0.084	0.084	-0.033
IgG4	0.219²	0.246¹	0.196²	0.137	0.106	0.186²	0.256¹	0.128
P-III-P								
IgA	0.027	-0.048	-0.025	0.263¹	0.194²	-0.013	0.295¹	0.238¹
IgE	-0.049	-0.260¹	0.051	-0.056	-0.178²	-0.304¹	-0.260¹	-0.194²
IgG1	0.097	-0.156	(-)	(-)	(-)	(-)	(-)	(-)
IgG3	0.215²	0.292¹	0.025	0.188²	0.216²	0.011	0.286¹	0.182²
IgG4	0.035	0.076	0.120	0.056	0.025	0.028	0.085	0.085
Type-IV								
IgA	-0.079	-0.067	0.032	0.038	-0.014	0.027	0.088	0.084
IgE	-0.030	-0.107	-0.041	-0.093	-0.062	-0.140	-0.072	0.002
IgG1	0.072	-0.057	(-)	(-)	(-)	(-)	(-)	(-)
IgG3	0.174²	0.150	0.073	0.053	0.020	-0.037	0.088	0.177²
IgG4	-0.032	-0.035	0.100	-0.031	-0.034	-0.007	0.032	-0.013

¹ $p < 0.01$, ² $p < 0.05$.

R values for IgG1 responses to the truncated PMs are not shown.

Figure 1. Nara, *et al.*




Figure 2. Nara, *et al.*




Figure 3. Nara, *et al.*

